Aktuellt
SENASTE
Redeye endorses this morning’s news that IRLAB has submitted a request for an end-of-phase II meeting, an important catalyst in our view as the meeting (that will be scheduled within 70 calendar days from receipt of the request) will be essential to determine the remaining clinical steps for the phase 3 ready asset Mesdopetam, targeting PD-LIDs. We hope to learn more soon about the upcoming meeting.
LÄS MER
